SCHEMBL35183

SCHEMBL35183

O=S(=O)(O)CCCCS(=O)(=O)O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 1/20 0.65
PTGS1 P23219 1/20 0.53
PDE4A P27815 1/20 0.53
LMNA P02545 1/20 0.53
SLC6A6 P31641 1/20 0.53
CYP2C19 P33261 1/20 0.53
BLM P54132 1/20 0.53
CA5A P35218 2/20 0.39
CA5B Q9Y2D0 2/20 0.39
EPHX2 P34913 1/20 0.38
TSHR P16473 3/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
NT5E P21589 1/20 0.33
CA4 P22748 1/20 0.33
CA6 P23280 1/20 0.33
CA7 P43166 1/20 0.33
CA9 Q16790 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
MEN1 O00255 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL563945 0.96 APP (0.61) APPPTGS1PDE4ALMNASLC6A6
SCHEMBL2288147 0.96 APP (0.61) APPPTGS1PDE4ALMNASLC6A6
SCHEMBL6695830 0.96 APP (0.61) APPPTGS1PDE4ALMNASLC6A6
SCHEMBL917843 0.96 APP (0.61) APPPTGS1PDE4ALMNASLC6A6
SCHEMBL1270542 0.96 APP (0.61) APPPTGS1PDE4ALMNASLC6A6
Hydrochloric Acid SCHEMBL8210048 0.96 APP (0.61) APPPTGS1PDE4ALMNASLC6A6
SCHEMBL6692218 0.96 APP (0.61) APPPTGS1PDE4ALMNASLC6A6
SCHEMBL1270406 0.96 APP (0.61) APPPTGS1PDE4ALMNASLC6A6
SCHEMBL10693026 0.96 APP (0.61) APPPTGS1PDE4ALMNASLC6A6
SCHEMBL922126 0.96 APP (0.61) APPPTGS1PDE4ALMNASLC6A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1430 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260115191-A1 Nilotinib Compositions with Enhanced Solubility NEOFORM BIOPHARMACEUTICAL LTD (CN) 2026-04-30 US claimed
US-12442728-B2 Preservative solution for heme protein, and method for stabilizing heme protein EIKEN KAGAKU KABUSHIKI KAISHA (JP) 2025-10-14 US claimed
CN-120129539-A Radionuclide composition and method for detecting tumor cells by using radionuclide composition 纽约州立大学研究基金会 2025-06-10 CN claimed
CN-119977129-A Butanedisulfonic acid waste liquid neutralization treatment device 山东鲁抗三叶生物制药有限公司 2025-05-13 CN claimed
CN-119753047-A Preparation process of high-purity butanedisulfonic acid ademetionine 江西诚志生物工程有限公司 2025-04-04 CN claimed
CN-119574729-A Method for detecting antioxidant in adenosylmethionine butanesulfonate for injection 石家庄四药有限公司 2025-03-07 CN claimed
CN-119499265-A Butanedisulfonic acid adenomethionine for injection and preparation method thereof 海南倍特药业有限公司 2025-02-25 CN claimed
CN-119439655-A Corrosion-resistant developing solution and preparation method and application thereof 上海戎洲芯科技有限公司 2025-02-14 CN claimed
CN-119103813-B Preparation method of high-temperature-resistant butanedisulfonic acid ademetionine for injection 成都天兴致远生物科技有限公司 2025-01-24 CN claimed
CN-116408051-B Sulfonic acid anion hybridization porous material, preparation method and ethylene-ethane separation method 中国石油天然气股份有限公司 2025-01-21 CN claimed
WO-1999059571-A1 USE OF AMYLOID INHIBITORS FOR MODULATING NEURONAL CELL DEATH NEUROCHEM, INC. (US) 1999-11-25 WO claimed
WO-1999045947-A1 IN VITRO FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES UNIVERSITY OF WASHINGTON (US) 1999-09-16 WO claimed
US-5840294-A INHIBITING AMYLOID DEPOSITION BY ADMINISTERING A THERAPEUTIC COMPOUND COMPRISING AN ANIONIC GROUP AND A CARRIER MOLECULE QUEEN'S UNIVERSITY AT KINGSTON (CA) 1998-11-24 US claimed
US-5776911-A Use of (S)-adenosyl-l-methionine (same) and its physiologically tolerated salts for treating reperfusion damage caused by temporary focal ischemia KNOLL AKTIENGESELLSCAHFT (DE) 1998-07-07 US claimed
EP-0814842-A1 METHOD FOR TREATING AMYLOIDOSIS Queen's University at Kingston (CA) 1998-01-07 EP claimed
US-5643562-A ANTIDEPOSIT AGENTS FOR PROTEINS FOR MEDICAL DIAGNOSIS OF DISEASES QUEEN'S UNIVERSITY OF KINGSTON (CA) 1997-07-01 US claimed
CN-1134401-A New-type scale-inhibiting dispersion agent for water treatment TIANJIN CHEMICAL INST MINISTRY (CN) 1996-10-30 CN claimed
WO-1996028187-A1 METHOD FOR TREATING AMYLOIDOSIS QUEEN'S UNIVERSITY AT KINGSTON (CA) 1996-09-19 WO claimed
EP-0501293-A1 Use of S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis determined by total parenteral nutrition BIORESEARCH S.p.A. (IT) 1992-09-02 EP claimed
US-4016236-A WET SPINNING AN ANISOTROPIC DOPE ASAHI KASEI KOGYO KABUSHIKI KAISHA (JA) 1977-04-05 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260115191-A1 Nilotinib Compositions with Enhanced Solubility TP53, PHF8, SMCHD1 APP 4625/4885PTGS1 3665/4885PDE4A 462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.